CJC-1295 With DAC
Also Known As: CJC-1295 DAC, CJC 1295 with DAC, CJC1295 DAC, GHRH analog with DAC, CJC-1295 Drug Affinity Complex, DAC-GRF, Modified GHRH long-acting, CJC 1295 extended release, CJC-1295 albumin-binding GHRH, Long-acting GHRH analog, Growth hormone releasing hormone analog DAC, CJC1295 with drug affinity complex, CJC with DAC, Drug Affinity Complex, long acting GHRH
CJC-1295 With DAC is a research-grade Long-acting synthetic GHRH analog with Drug Affinity Complex targeting GHRH receptor studied in Muscle Growth & Performance research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Research Compound - No approved human use; sold for laboratory research only.
A long-acting growth-hormone-releasing peptide; banned in sport.
At A Glance
| Category | Muscle Growth & Performance |
|---|---|
| Compound Class | Long-acting synthetic GHRH analog with Drug Affinity Complex (DAC) albumin-binding moiety |
| Molecular Target | GHRH receptor (GHRHR) on pituitary somatotrophs; sustained GH and IGF-1 elevation |
| Molecular Weight | 3647.1 Da |
| Amino Acid Sequence | tetrasubstituted GRF(1-29) + DAC |
| CAS Number | 446262-90-4 |
| Half-Life | ~6-8 days (albumin-bound, DAC) |
| WADA Status | prohibited |
| Evidence Tier | Research Compound |
Mechanism Of Action
It attaches to a larger protein in your blood (albumin), which stops your body from destroying it quickly. This allows it to constantly knock on the pituitary gland's door to release growth hormone for days.
Studied For
- GH pulsatile release research
- GH-axis anti-aging
- Growth hormone deficiency
- Extended GH secretion
- Anti-aging / longevity via GH axis
- Muscle growth via GH axis
- Body composition improvement
- Fat reduction via GH
- Sleep quality enhancement
- IGF-1 elevation research
- Recovery and repair via GH axis
- Bone density via GH stimulation
- Collagen synthesis via GH axis
- Metabolic rate increase
- Adult GH deficiency models
- GH secretagogue research
- continuous GH release
- muscle growth
- fat loss
- IGF-1 elevation
- recovery
Reported Research Findings
A 2006 human Phase 1/2 study showed single doses raised growth hormone for about 6 days and IGF-1 for 9 to 11 days. Limited evidence beyond early trials.
Safety And Handling Notes
Injection-site reactions, facial flushing, headache, water retention. Sustained non-pulsatile growth-hormone elevation raises a theoretical desensitization concern.
Not approved; no chronic-use safety data; general growth-hormone-axis risks apply. WADA-prohibited. Research use only.
Regulatory Status
Not FDA-approved; research chemical; WADA S2.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.